TSE:RVX

Resverlogix News Headlines

C$0.86
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
C$0.85
Now: C$0.86
C$0.88
50-Day Range
C$0.85
MA: C$0.91
C$1.02
52-Week Range
C$0.56
Now: C$0.86
C$1.52
Volume42,574 shs
Average Volume57,252 shs
Market CapitalizationC$202.07 million
P/E Ratio78.18
Dividend YieldN/A
BetaN/A

Headlines

Resverlogix (TSE RVX) News Headlines Today

SourceHeadline
Apabetalones Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell - GlobeNewswireApabetalone's Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell - GlobeNewswire
globenewswire.com - March 17 at 12:40 PM
Apabetalone’s Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal CellApabetalone’s Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell
finance.yahoo.com - March 17 at 12:40 PM
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Mercks Immune Check Point Inhibitor KEYTRUDA - StreetInsider.comZenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck's Immune Check Point Inhibitor KEYTRUDA - StreetInsider.com
streetinsider.com - March 15 at 1:45 PM
Apabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells - GlobeNewswireApabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells - GlobeNewswire
globenewswire.com - March 15 at 1:45 PM
Apabetalone Treatment Prevents COVID-19 Infection of Human Lung CellsApabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells
finance.yahoo.com - March 15 at 1:45 PM
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDAZenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
finance.yahoo.com - March 15 at 8:45 AM
Resverlogix Announces Change in Fiscal Year-End to December 31 - Yahoo FinanceResverlogix Announces Change in Fiscal Year-End to December 31 - Yahoo Finance
finance.yahoo.com - March 13 at 12:27 PM
Resverlogix Announces Change in Fiscal Year-End to December 31 - GlobeNewswireResverlogix Announces Change in Fiscal Year-End to December 31 - GlobeNewswire
globenewswire.com - March 12 at 9:24 PM
New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19
finance.yahoo.com - March 3 at 12:15 PM
Resverlogix Corp. (RVX.TO)Resverlogix Corp. (RVX.TO)
uk.finance.yahoo.com - January 30 at 5:48 PM
Resverlogix Reschedules Update Webcast and Conference CallResverlogix Reschedules Update Webcast and Conference Call
finance.yahoo.com - January 27 at 7:21 PM
Resverlogix Announces Update Webcast and Conference CallResverlogix Announces Update Webcast and Conference Call
finance.yahoo.com - January 19 at 5:04 PM
Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart FailureApabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
finance.yahoo.com - January 12 at 10:29 AM
Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud BaeshenResverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen
finance.yahoo.com - December 22 at 6:47 PM
Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19) Exposure Significantly Reduces Viral Infection – Confirms Plans for COVID-19 Clinical TrialResverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19) Exposure Significantly Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
finance.yahoo.com - December 22 at 8:41 AM
What Type Of Shareholders Own The Most Number of Resverlogix Corp. (TSE:RVX) Shares?What Type Of Shareholders Own The Most Number of Resverlogix Corp. (TSE:RVX) Shares?
finance.yahoo.com - December 11 at 2:49 PM
Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical EpigeneticsResverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
finance.yahoo.com - November 12 at 8:35 AM
Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control MarkersResverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
finance.yahoo.com - November 2 at 9:54 AM
Zenith Confirms Interim Filings on SEDAR - Yahoo FinanceZenith Confirms Interim Filings on SEDAR - Yahoo Finance
finance.yahoo.com - October 28 at 2:45 PM
Zenith Confirms Interim Filings on SEDARZenith Confirms Interim Filings on SEDAR
finance.yahoo.com - October 28 at 2:45 PM
A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms - GlobeNewswireA Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms - GlobeNewswire
globenewswire.com - October 26 at 9:00 AM
A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine StormsA Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms
finance.yahoo.com - October 26 at 9:00 AM
Resverlogix Announces Presentations at Leading Scientific Conferences Toronto Stock Exchange:RVX - GlobeNewswireResverlogix Announces Presentations at Leading Scientific Conferences Toronto Stock Exchange:RVX - GlobeNewswire
globenewswire.com - October 15 at 1:33 PM
Resverlogix Announces Presentations at Leading Scientific ConferencesResverlogix Announces Presentations at Leading Scientific Conferences
markets.businessinsider.com - October 15 at 8:32 AM
Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet - GlobeNewswireResverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet - GlobeNewswire
globenewswire.com - October 14 at 1:54 PM
Resverlogix Corp: Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance SheetResverlogix Corp: Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet
finanznachrichten.de - October 14 at 8:53 AM
Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance SheetResverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet
markets.businessinsider.com - October 14 at 8:53 AM
Resverlogix Corp. Registered Sh (RFS.SG)Resverlogix Corp. Registered Sh (RFS.SG)
in.finance.yahoo.com - October 11 at 10:11 PM
Resverlogix Announces $13 Million Private PlacementResverlogix Announces $13 Million Private Placement
benzinga.com - October 8 at 7:48 PM
Resverlogix Announces $13 Million Private Placement Toronto Stock Exchange:RVX - GlobeNewswireResverlogix Announces $13 Million Private Placement Toronto Stock Exchange:RVX - GlobeNewswire
globenewswire.com - October 6 at 9:23 AM
Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications - StreetInsider.comZenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications - StreetInsider.com
streetinsider.com - October 5 at 1:33 PM
Resverlogix Confirms Interim Filings on SEDAR - Yahoo FinanceResverlogix Confirms Interim Filings on SEDAR - Yahoo Finance
finance.yahoo.com - October 2 at 10:25 PM
Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews - GlobeNewswireResverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews - GlobeNewswire
globenewswire.com - September 15 at 9:56 AM
Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research ReviewsResverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews
finance.yahoo.com - September 15 at 9:56 AM
Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation - GlobeNewswireResverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation - GlobeNewswire
globenewswire.com - September 8 at 11:47 AM
Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in InnovationResverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation
finance.yahoo.com - September 8 at 11:47 AM
Resverlogix Provides Update Regarding Extension of its Filing Calendar - GlobeNewswireResverlogix Provides Update Regarding Extension of its Filing Calendar - GlobeNewswire
globenewswire.com - August 28 at 8:55 PM
Resverlogix Provides Update Regarding Extension of its Filing CalendarResverlogix Provides Update Regarding Extension of its Filing Calendar
finance.yahoo.com - August 28 at 8:55 PM
Zenith Announces Extension of its Filing Calendar Based on Continuous Disclosure ExemptionZenith Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption
finance.yahoo.com - August 26 at 10:58 PM
Resverlogix Announces Private Placement Toronto Stock Exchange:RVX - GlobeNewswireResverlogix Announces Private Placement Toronto Stock Exchange:RVX - GlobeNewswire
globenewswire.com - August 14 at 7:52 PM
Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics - GlobeNewswireResverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics - GlobeNewswire
globenewswire.com - August 4 at 1:14 PM
Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs - Yahoo FinanceZenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs - Yahoo Finance
finance.yahoo.com - July 29 at 1:15 PM
Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption - Yahoo FinanceResverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption - Yahoo Finance
finance.yahoo.com - July 29 at 8:14 AM
Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption - StreetInsider.comResverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption - StreetInsider.com
www.streetinsider.com - July 28 at 10:14 PM
Resverlogix Secures One-Year Extension of Maturity Date of Debenture - GlobeNewswireResverlogix Secures One-Year Extension of Maturity Date of Debenture - GlobeNewswire
www.globenewswire.com - July 22 at 9:11 AM
Resverlogix Secures One-Year Extension of Maturity Date of DebentureResverlogix Secures One-Year Extension of Maturity Date of Debenture
finance.yahoo.com - July 22 at 9:11 AM
The Market’s Major Volatility Indexes Are Signaling a Replay of March’s DeclineThe Market’s Major Volatility Indexes Are Signaling a Replay of March’s Decline
finance.yahoo.com - June 25 at 5:56 PM
Volatility Indexes Have Bottomed Again. That’s Bad News for Stocks.Volatility Indexes Have Bottomed Again. That’s Bad News for Stocks.
finance.yahoo.com - June 25 at 12:55 PM
Resverlogix Corp. - Baystreet.caResverlogix Corp. - Baystreet.ca
www.baystreet.ca - June 22 at 2:17 PM
BRIEF-Resverlogix Reaches Agreement With FDA For Key Aspects Of Apabetalone Registration Enabling Study - ReutersBRIEF-Resverlogix Reaches Agreement With FDA For Key Aspects Of Apabetalone Registration Enabling Study - Reuters
www.reuters.com - June 22 at 8:14 AM
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.